---
schema_version: "secwatch.filing_event.v1"
accession: "0001618835-22-000142"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:12:48.917104+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences appoints Jenny Yip from Adjuvant Capital to board of directors

## Summary
- Jenny Yip, Managing Partner at Adjuvant Capital, elected to Evofem board effective August 2, 2022.
- Adjuvant Capital previously invested $25 million to fund Phase 3 EVOGUARD trial for Phexxi in chlamydia/gonorrhea prevention.
- Top-line results from EVOGUARD trial expected fall 2022.
- Board expands from five to six independent directors with Yip's appointment.
- Yip's term expires at 2023 annual meeting; standard indemnification agreement entered.

## SEC filing metadata
- accession: 0001618835-22-000142
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000142/0001618835-22-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000142/evfm-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001618835-22-000142
- JSON: https://secwatch.observer/filing/0001618835-22-000142.json
- Plain text: https://secwatch.observer/filing/0001618835-22-000142.txt

## Key facts
- Executive change
  Jenny Yip was elected as Director at Evofem Biosciences, Inc..
  - Action: elected
  - Role: Director
  source text: On August 2, 2022, the Board of Directors (the “Board”) of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), elected Jenny Yip, to the Board to fill the existing vacancy on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000142/0001618835-22-000142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.